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Allogeneic unrelated hematopoietic stem cell transplants
(HSCT) are complex procedures that need adequate hospital
infrastructure, a competent team, high-cost procedures and
medications. Most transplants that are performed in Brazil
are paid by the government. The national health system
reimburses the hospital U$ 35,801.00 as a ﬂat rate. The
government has recently increased this amount by 60% but
there are not national studies to use to evaluate the appro-
priateness of this amount. The objective of this study was to
retrospectively evaluate the cost of ten consecutive unrelated
donor HSCT performed in our institution.
Methods: Theprojectwas approved byour IRB (CEP-UNIFESP
#1875/11) and granted waiver to request consent. The costs
wereevaluated fromtheﬁrst appointmentuntil oneyear after
transplant or death divided as 1) pre-HSCT, 2) conditioning
therapy, 3) from the day of transplant until ﬁrst discharge, 4)
until D+100, 5) until D+180, and 6) until D+360. The costs
included medications, supplies, blood transfusions, labora-
tory, imaging and the cost of the ward. Housing and out-of
pocket costs or loss of income were not evaluated. Patients
were scored 1 to 3 according to the Pediatric EBMT score.
Results: Ten consecutive children 2-14 years of age under-
went unrelated donor HSCT from June, 2010 to May, 2011.
Diagnoses were ALL (4). AML (3), lymphoma (2), and aplastic
anemia (1). Three patients had early disease and others were
in advanced phases of the disease. Eight were CMV positive.
Five hadmarrow and ﬁve cord blood transplants. Themedian
interval to transplant was 3.7 years from diagnosis and 80
days from referral. The patients remained hospitalized for
a median of 80 days (21-50). Median time to engraftment
was D+22 (12-56) and six had complications and needed
Intensive Care support. Of the 10 children, seven were dis-
charged but three eventually relapsed and died, overall
survival is 50%. The median total cost during the ﬁrst year
was U$118,908.00 (mean U$ 139,861.00) e 44% of that spent
within the ﬁrst 100 days post HSCT. The ﬁrst admission had
a median total cost of U$ 64,385.00 (14,400 e 166,792). Total
costs were approximately 40% higher than the direct cost.
The highest costs were blood products and medications. No
relationship was found between cost and age, gender, graft
source of Pediatric EBMT-score.
Conclusion: Unrelated-donor HSCT is an expensive proce-
dure and the government only partially reimburses its cost.
Even with a 60% increase in reimbursement there will be
a deﬁcit in more than half of the procedures. We are working
to increase the amount paid for speciﬁc complications and
will have to continue to ﬁnd alternative resources to pay for
the transplants.343
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Materials and Methods: We retrospectively reviewed 76
medical records of patients older than 50 years receiving an
allogeneic HSCT in our centers. We evaluated the following
characteristics: sex, age, diagnosis, stage, comorbidities
(according to the HCT-CI score), type of donor, histocom-
patibility, conditioning and immunosupression. We analyzed
the incidence and severity of Graft-vs-Host disease (GVHD)
and treatment related mortality (TRM) with Chi Square and
Overall Survival (OS) and Disease Free Survival (DFS) with
Kaplan Meier. For multivariate analysis (MA) we used Cox
regression model for time dependant outcomes and logistic
regression for dichotomic variables, considering signiﬁcant
a P < .05.
Results: Between March 1998 and June 2012, 76 transplants
were performed with a median follow up of 1.9 years.
Fourteen patients were older than 60 years, 51 were male,
HCT-CI score was 0 (41%), 1 (36%), 2 (23%), common diag-
nosis were AML (35%), MDS (30%) and MPN (20%), 65% were
in late stage, 80% received a transplant from a MRD, 37%
received FluMel conditioning regimen, 32% FluBu and 12%
BuCy, 66% received tacrolimus (Fk) based regimen and 34%
cyclosporine. Acute GVHD (aGVHD) incidencewas 51%, aGVH
grade II-IV 29%. AML patients had a lower incidence of
aGVHD (36% vs. 61%, P < .03) still signiﬁcant in MA (HR 0.27;
95% CI 0.07-0.98;P¼ .04) as well as FluMel conditioning (33%
vs. 59%,P¼ .02), in contrast to unrelated donor (URD) (aGVHD
GII-IV 53% vs. 23%,P¼ .02). Chronic GVHD incidence was 33%,
extensive in 10%. Early TRM (day 100) was 17% and global
30%. Female patients had lower early TRM (4% vs. 25%,P ¼
.02) opposite to HCT-CI score 2 patients that experienced
a higher global TRM (58% vs. 26%, P < .04) still signiﬁcant in
MA (HR 4.6; 95% CI 1.03-20.9;P¼ .04) as well as MPN patients
(64% vs. 25%, P < .01) also signiﬁcant in MA (HR 7.2; 95% CI
1.20-43.7;P ¼ .03). OS was 43% (1 year) and 20% (3 years).
Patients older than 60 had a higher OS (1/3 years 61/43% vs.
38/14%;P ¼ .01), while FluBu was associated to a lower OS (1/
3 years 25/10% vs. 49/23%, P < .05), not signiﬁcant in MA.
Regarding immunosuppressant, the use of Fk was associated
with a higher OS (1/3 years 44/20% vs. 19/6%, P < .01)
signiﬁcant in MA (HR 0.45; 95% CI 0.2-0.9;P ¼ .04) and DFS
(1/3 years 33/18% vs. 11/5%,P ¼ .01).
Conclusion: According to the literature, URD is associated
with a higher incidence of clinical signiﬁcant aGVHD (P¼ .02)
and FluMel presented lower incidence of aGVHD as well as
AML patients. Regarding TRM female patients had a lower
early TRM and lower HCT-CI score had lower global TRM.
FluBu was associated with a lower OS, while Fk patients had
a higher OS and DFS. Interestingly patients older than 60 had
higher OS not signiﬁcant in MA, probably due to a better
selection: none had HCT-CI higher than 1, only 1 patient
received an URD transplant, most of them received Fk base
immunosuppressant and all of them received a NMA trans-
plant.344
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